Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 79 entries
Sorted by: Best Match Show Resources per page
Geologically-inspired strong bulk ceramics made with water at room temperature.

Nature communications

Bouville F, Studart AR.
PMID: 28262760
Nat Commun. 2017 Mar 06;8:14655. doi: 10.1038/ncomms14655.

Dense ceramic materials can form in nature under mild temperatures in water. By contrast, man-made ceramics often require sintering temperatures in excess of 1,400 °C for densification. Chemical strategies inspired by biomineralization processes have been demonstrated but remain limited...

Cite
Bouville F, Studart AR. Geologically-inspired strong bulk ceramics made with water at room temperature. Nat Commun. 2017;8:14655doi: 10.1038/ncomms14655.
Bouville, F., & Studart, A. R. (2017). Geologically-inspired strong bulk ceramics made with water at room temperature. Nature communications, 814655. https://doi.org/10.1038/ncomms14655
Bouville, Florian, and Studart, André R. "Geologically-inspired strong bulk ceramics made with water at room temperature." Nature communications vol. 8 (2017): 14655. doi: https://doi.org/10.1038/ncomms14655
Bouville F, Studart AR. Geologically-inspired strong bulk ceramics made with water at room temperature. Nat Commun. 2017 Mar 06;8:14655. doi: 10.1038/ncomms14655. PMID: 28262760; PMCID: PMC5343517.
Copy Download .nbib Format: NLM
Nonadiabatic phenomena during magnetic trap confinement and their influence on maximum x-ray energy from electron-cyclotron-resonance-heated plasmas.

Physical review. E, Statistical, nonlinear, and soft matter physics

Serebrennikov KS, Gaudin C, Buzzi JM, Bruneteau J, Rouille C.
PMID: 11308954
Phys Rev E Stat Nonlin Soft Matter Phys. 2001 Apr;63(4):046405. doi: 10.1103/PhysRevE.63.046405. Epub 2001 Mar 26.

Nonadiabatic effects during the confinement of energetic electrons with a gyroradius comparable with the magnetic field scale have been studied with a phase section technique. The appearance of a hot electron component is a characteristic feature of electron-cyclotron-resonance-heated plasma...

Cite
Serebrennikov KS, Gaudin C, Buzzi JM, et al. Nonadiabatic phenomena during magnetic trap confinement and their influence on maximum x-ray energy from electron-cyclotron-resonance-heated plasmas. Phys Rev E Stat Nonlin Soft Matter Phys. 2001;63(4):046405doi: 10.1103/PhysRevE.63.046405.
Serebrennikov, K. S., Gaudin, C., Buzzi, J. M., Bruneteau, J., & Rouille, C. (2001). Nonadiabatic phenomena during magnetic trap confinement and their influence on maximum x-ray energy from electron-cyclotron-resonance-heated plasmas. Physical review. E, Statistical, nonlinear, and soft matter physics, 63(4), 046405. https://doi.org/10.1103/PhysRevE.63.046405
Serebrennikov, K S, et al. "Nonadiabatic phenomena during magnetic trap confinement and their influence on maximum x-ray energy from electron-cyclotron-resonance-heated plasmas." Physical review. E, Statistical, nonlinear, and soft matter physics vol. 63,4 (2001): 046405. doi: https://doi.org/10.1103/PhysRevE.63.046405
Serebrennikov KS, Gaudin C, Buzzi JM, Bruneteau J, Rouille C. Nonadiabatic phenomena during magnetic trap confinement and their influence on maximum x-ray energy from electron-cyclotron-resonance-heated plasmas. Phys Rev E Stat Nonlin Soft Matter Phys. 2001 Apr;63(4):046405. doi: 10.1103/PhysRevE.63.046405. Epub 2001 Mar 26. PMID: 11308954.
Copy Download .nbib Format: NLM
3D printing of sacrificial templates into hierarchical porous materials.

Scientific reports

Alison L, Menasce S, Bouville F, Tervoort E, Mattich I, Ofner A, Studart AR.
PMID: 30674930
Sci Rep. 2019 Jan 23;9(1):409. doi: 10.1038/s41598-018-36789-z.

Hierarchical porous materials are widespread in nature and find an increasing number of applications as catalytic supports, biological scaffolds and lightweight structures. Recent advances in additive manufacturing and 3D printing technologies have enabled the digital fabrication of porous materials...

Cite
Alison L, Menasce S, Bouville F, et al. 3D printing of sacrificial templates into hierarchical porous materials. Sci Rep. 2019;9(1):409doi: 10.1038/s41598-018-36789-z.
Alison, L., Menasce, S., Bouville, F., Tervoort, E., Mattich, I., Ofner, A., & Studart, A. R. (2019). 3D printing of sacrificial templates into hierarchical porous materials. Scientific reports, 9(1), 409. https://doi.org/10.1038/s41598-018-36789-z
Alison, Lauriane, et al. "3D printing of sacrificial templates into hierarchical porous materials." Scientific reports vol. 9,1 (2019): 409. doi: https://doi.org/10.1038/s41598-018-36789-z
Alison L, Menasce S, Bouville F, Tervoort E, Mattich I, Ofner A, Studart AR. 3D printing of sacrificial templates into hierarchical porous materials. Sci Rep. 2019 Jan 23;9(1):409. doi: 10.1038/s41598-018-36789-z. PMID: 30674930; PMCID: PMC6344549.
Copy Download .nbib Format: NLM
Idarucizumab (Praxbind.

Future science OA

Kalmanovich E, Battistella P, Rouviere P, Albat B, Frapier JM, Demaria R, Huet F, Agullo A, Mourad M, Colson P, Leclercq F, Gaudard P, Roubille F.
PMID: 33815827
Future Sci OA. 2021 Feb 15;7(4):FSO689. doi: 10.2144/fsoa-2020-0186.

BACKGROUND: Novel oral anticoagulants are used in atrial fibrillation. Idarucizumab has been approved for reversal of dabigatran in situations of life-threatening hemorrhage or emergency surgery.OBJECTIVES: We report a single center experience of ten patients on dabigatran therapy who were...

Cite
Kalmanovich E, Battistella P, Rouviere P, et al. Idarucizumab (Praxbind. Future Sci OA. 2021;7(4):FSO689doi: 10.2144/fsoa-2020-0186.
Kalmanovich, E., Battistella, P., Rouviere, P., Albat, B., Frapier, J. M., Demaria, R., Huet, F., Agullo, A., Mourad, M., Colson, P., Leclercq, F., Gaudard, P., & Roubille, F. (2021). Idarucizumab (Praxbind. Future science OA, 7(4), FSO689. https://doi.org/10.2144/fsoa-2020-0186
Kalmanovich, Eran, et al. "Idarucizumab (Praxbind." Future science OA vol. 7,4 (2021): FSO689. doi: https://doi.org/10.2144/fsoa-2020-0186
Kalmanovich E, Battistella P, Rouviere P, Albat B, Frapier JM, Demaria R, Huet F, Agullo A, Mourad M, Colson P, Leclercq F, Gaudard P, Roubille F. Idarucizumab (Praxbind. Future Sci OA. 2021 Feb 15;7(4):FSO689. doi: 10.2144/fsoa-2020-0186. PMID: 33815827; PMCID: PMC8015660.
Copy Download .nbib Format: NLM
Impact of a simulation-based training on the experience of the beginning of residency.

La Revue de medecine interne

Mercuzot C, Debien B, Riviere É, Martis N, Sanges S, Galland J, Kouchit Y, Fesler P, Roubille C.
PMID: 34303548
Rev Med Interne. 2021 Nov;42(11):756-763. doi: 10.1016/j.revmed.2021.07.002. Epub 2021 Jul 22.

INTRODUCTION: We aimed to evaluate the impact of an immersive simulation session on the experience of the beginning of residency.METHODS: The interventional group consisted of newly recruited residents in 2019, who participated in the workshop presenting four emergency scenarios...

Cite
Mercuzot C, Debien B, Riviere É, et al. Impact of a simulation-based training on the experience of the beginning of residency. Rev Med Interne. 2021;42(11):756-763doi: 10.1016/j.revmed.2021.07.002.
Mercuzot, C., Debien, B., Riviere, �. �., Martis, N., Sanges, S., Galland, J., Kouchit, Y., Fesler, P., & Roubille, C. (2021). Impact of a simulation-based training on the experience of the beginning of residency. La Revue de medecine interne, 42(11), 756-763. https://doi.org/10.1016/j.revmed.2021.07.002
Mercuzot, C, et al. "Impact of a simulation-based training on the experience of the beginning of residency." La Revue de medecine interne vol. 42,11 (2021): 756-763. doi: https://doi.org/10.1016/j.revmed.2021.07.002
Mercuzot C, Debien B, Riviere É, Martis N, Sanges S, Galland J, Kouchit Y, Fesler P, Roubille C. Impact of a simulation-based training on the experience of the beginning of residency. Rev Med Interne. 2021 Nov;42(11):756-763. doi: 10.1016/j.revmed.2021.07.002. Epub 2021 Jul 22. PMID: 34303548.
Copy Download .nbib Format: NLM
Low-dose colchicine prevents sympathetic denervation after myocardial ischemia-reperfusion: a new potential protective mechanism.

Future science OA

Huet F, Fauconnier J, Legall M, Sicard P, Lozza C, Lacampagne A, Roubille F.
PMID: 33437519
Future Sci OA. 2020 Nov 23;7(2):FSO656. doi: 10.2144/fsoa-2020-0151.

PURPOSE: To evaluate the impact of colchicine on sympathetic denervation after acute myocardial infarction (AMI).MATERIALS & METHODS: Ischemia/Reperfusion was induced in C57BL/6J male mice. Left coronary artery was ligated during 45 min followed by reperfusion. 400 μg/kg of colchicine...

Cite
Huet F, Fauconnier J, Legall M, et al. Low-dose colchicine prevents sympathetic denervation after myocardial ischemia-reperfusion: a new potential protective mechanism. Future Sci OA. 2020;7(2):FSO656doi: 10.2144/fsoa-2020-0151.
Huet, F., Fauconnier, J., Legall, M., Sicard, P., Lozza, C., Lacampagne, A., & Roubille, F. (2020). Low-dose colchicine prevents sympathetic denervation after myocardial ischemia-reperfusion: a new potential protective mechanism. Future science OA, 7(2), FSO656. https://doi.org/10.2144/fsoa-2020-0151
Huet, Fabien, et al. "Low-dose colchicine prevents sympathetic denervation after myocardial ischemia-reperfusion: a new potential protective mechanism." Future science OA vol. 7,2 (2020): FSO656. doi: https://doi.org/10.2144/fsoa-2020-0151
Huet F, Fauconnier J, Legall M, Sicard P, Lozza C, Lacampagne A, Roubille F. Low-dose colchicine prevents sympathetic denervation after myocardial ischemia-reperfusion: a new potential protective mechanism. Future Sci OA. 2020 Nov 23;7(2):FSO656. doi: 10.2144/fsoa-2020-0151. PMID: 33437519; PMCID: PMC7787178.
Copy Download .nbib Format: NLM
Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT).

European heart journal. Quality of care & clinical outcomes

Samuel M, Tardif JC, Khairy P, Roubille F, Waters DD, Grégoire JC, Pinto FJ, Maggioni AP, Diaz R, Berry C, Koenig W, Ostadal P, Lopez-Sendon J, Gamra H, Kiwan GS, Dubé MP, Provencher M, Orfanos A, Blondeau L, Kouz S, L'Allier PL, Ibrahim R, Bouabdallaoui N, Mitchell D, Guertin MC, Lelorier J.
PMID: 32407460
Eur Heart J Qual Care Clin Outcomes. 2021 Sep 16;7(5):486-495. doi: 10.1093/ehjqcco/qcaa045.

AIMS: In the randomized, placebo-controlled Colchicine Cardiovascular Outcomes Trial (COLCOT) of 4745 patients enrolled within 30 days after myocardial infarction (MI), low-dose colchicine (0.5 mg once daily) reduced the incidence of the primary composite endpoint of cardiovascular death, resuscitated...

Cite
Samuel M, Tardif JC, Khairy P, et al. Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). Eur Heart J Qual Care Clin Outcomes. 2021;7(5):486-495doi: 10.1093/ehjqcco/qcaa045.
Samuel, M., Tardif, J. C., Khairy, P., Roubille, F., Waters, D. D., Grégoire, J. C., Pinto, F. J., Maggioni, A. P., Diaz, R., Berry, C., Koenig, W., Ostadal, P., Lopez-Sendon, J., Gamra, H., Kiwan, G. S., Dubé, M. P., Provencher, M., Orfanos, A., Blondeau, L., Kouz, S., L'Allier, P. L., Ibrahim, R., Bouabdallaoui, N., Mitchell, D., Guertin, M. C., & Lelorier, J. (2021). Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). European heart journal. Quality of care & clinical outcomes, 7(5), 486-495. https://doi.org/10.1093/ehjqcco/qcaa045
Samuel, Michelle, et al. "Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)." European heart journal. Quality of care & clinical outcomes vol. 7,5 (2021): 486-495. doi: https://doi.org/10.1093/ehjqcco/qcaa045
Samuel M, Tardif JC, Khairy P, Roubille F, Waters DD, Grégoire JC, Pinto FJ, Maggioni AP, Diaz R, Berry C, Koenig W, Ostadal P, Lopez-Sendon J, Gamra H, Kiwan GS, Dubé MP, Provencher M, Orfanos A, Blondeau L, Kouz S, L'Allier PL, Ibrahim R, Bouabdallaoui N, Mitchell D, Guertin MC, Lelorier J. Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). Eur Heart J Qual Care Clin Outcomes. 2021 Sep 16;7(5):486-495. doi: 10.1093/ehjqcco/qcaa045. PMID: 32407460; PMCID: PMC8445085.
Copy Download .nbib Format: NLM
Effect of Colchicine on Myocardial Injury in Acute Myocardial Infarction.

Circulation

Mewton N, Roubille F, Bresson D, Prieur C, Bouleti C, Bochaton T, Ivanes F, Dubreuil O, Biere L, Hayek A, Derimay F, Akodad M, Alos B, Haider L, El Jonhy N, Daw R, De Bourguignon C, Dhelens C, Finet G, Bonnefoy-Cudraz E, Bidaux G, Boutitie F, Maucort-Boulch D, Croisille P, Rioufol G, Prunier F, Angoulvant D.
PMID: 34420373
Circulation. 2021 Sep 14;144(11):859-869. doi: 10.1161/CIRCULATIONAHA.121.056177. Epub 2021 Aug 23.

BACKGROUND: Inflammation is a key factor of myocardial damage in reperfused ST-segment-elevation myocardial infarction. We hypothesized that colchicine, a potent anti-inflammatory agent, may reduce infarct size (IS) and left ventricular (LV) remodeling at the acute phase of ST-segment-elevation myocardial...

Cite
Mewton N, Roubille F, Bresson D, et al. Effect of Colchicine on Myocardial Injury in Acute Myocardial Infarction. Circulation. 2021;144(11):859-869doi: 10.1161/CIRCULATIONAHA.121.056177.
Mewton, N., Roubille, F., Bresson, D., Prieur, C., Bouleti, C., Bochaton, T., Ivanes, F., Dubreuil, O., Biere, L., Hayek, A., Derimay, F., Akodad, M., Alos, B., Haider, L., El Jonhy, N., Daw, R., De Bourguignon, C., Dhelens, C., Finet, G., Bonnefoy-Cudraz, E., Bidaux, G., Boutitie, F., Maucort-Boulch, D., Croisille, P., Rioufol, G., Prunier, F., & Angoulvant, D. (2021). Effect of Colchicine on Myocardial Injury in Acute Myocardial Infarction. Circulation, 144(11), 859-869. https://doi.org/10.1161/CIRCULATIONAHA.121.056177
Mewton, Nathan, et al. "Effect of Colchicine on Myocardial Injury in Acute Myocardial Infarction." Circulation vol. 144,11 (2021): 859-869. doi: https://doi.org/10.1161/CIRCULATIONAHA.121.056177
Mewton N, Roubille F, Bresson D, Prieur C, Bouleti C, Bochaton T, Ivanes F, Dubreuil O, Biere L, Hayek A, Derimay F, Akodad M, Alos B, Haider L, El Jonhy N, Daw R, De Bourguignon C, Dhelens C, Finet G, Bonnefoy-Cudraz E, Bidaux G, Boutitie F, Maucort-Boulch D, Croisille P, Rioufol G, Prunier F, Angoulvant D. Effect of Colchicine on Myocardial Injury in Acute Myocardial Infarction. Circulation. 2021 Sep 14;144(11):859-869. doi: 10.1161/CIRCULATIONAHA.121.056177. Epub 2021 Aug 23. PMID: 34420373; PMCID: PMC8462445.
Copy Download .nbib Format: NLM
CLEO: a multidimensional tool to assess clinical, economic and organisational impacts of pharmacists' interventions.

European journal of hospital pharmacy : science and practice

Vo HT, Charpiat B, Chanoine S, Juste M, Roubille R, Rose FX, Conort O, Allenet B, Bedouch P.
PMID: 33883205
Eur J Hosp Pharm. 2021 Jul;28(4):193-200. doi: 10.1136/ejhpharm-2020-002642. Epub 2021 Apr 21.

OBJECTIVES: Clinical pharmacists' interventions (PIs) are an important element in ensuring good pharmaceutical care. We aimed to develop and validate a comprehensive multidimensional tool for assessing the potential impact of PIs for daily practice of medication review.METHODS: Experts of...

Cite
Vo HT, Charpiat B, Chanoine S, et al. CLEO: a multidimensional tool to assess clinical, economic and organisational impacts of pharmacists' interventions. Eur J Hosp Pharm. 2021;28(4):193-200doi: 10.1136/ejhpharm-2020-002642.
Vo, H. T., Charpiat, B., Chanoine, S., Juste, M., Roubille, R., Rose, F. X., Conort, O., Allenet, B., Bedouch, P. (2021). CLEO: a multidimensional tool to assess clinical, economic and organisational impacts of pharmacists' interventions. European journal of hospital pharmacy : science and practice, 28(4), 193-200. https://doi.org/10.1136/ejhpharm-2020-002642
Vo, Ha Thi, et al. "CLEO: a multidimensional tool to assess clinical, economic and organisational impacts of pharmacists' interventions." European journal of hospital pharmacy : science and practice vol. 28,4 (2021): 193-200. doi: https://doi.org/10.1136/ejhpharm-2020-002642
Vo HT, Charpiat B, Chanoine S, Juste M, Roubille R, Rose FX, Conort O, Allenet B, Bedouch P. CLEO: a multidimensional tool to assess clinical, economic and organisational impacts of pharmacists' interventions. Eur J Hosp Pharm. 2021 Jul;28(4):193-200. doi: 10.1136/ejhpharm-2020-002642. Epub 2021 Apr 21. PMID: 33883205; PMCID: PMC8239266.
Copy Download .nbib Format: NLM
COVID-19 Disparities by Gender and Income: Evidence from the Philippines.

International labour review

Lavado RF, Nowacka K, Raitzer D, van der Meulen Rodgers Y, Zveglich JE.
PMID: 34548683
Int Labour Rev. 2021 Jul 24; doi: 10.1111/ilr.12226. Epub 2021 Jul 24.

The COVID-19 pandemic and resulting containment policies have hit the Philippines harder than most developing countries. The government's lockdown is among the strictest globally, and school closures are the lengthiest on a blanket basis. This paper uses a novel...

Cite
Lavado RF, Nowacka K, Raitzer D, et al. COVID-19 Disparities by Gender and Income: Evidence from the Philippines. Int Labour Rev. 2021;doi: 10.1111/ilr.12226.
Lavado, R. F., Nowacka, K., Raitzer, D., van der Meulen Rodgers, Y., & Zveglich, J. E. (2021). COVID-19 Disparities by Gender and Income: Evidence from the Philippines. International labour review, . https://doi.org/10.1111/ilr.12226
Lavado, Rouselle F, et al. "COVID-19 Disparities by Gender and Income: Evidence from the Philippines." International labour review vol. (2021). doi: https://doi.org/10.1111/ilr.12226
Lavado RF, Nowacka K, Raitzer D, van der Meulen Rodgers Y, Zveglich JE. COVID-19 Disparities by Gender and Income: Evidence from the Philippines. Int Labour Rev. 2021 Jul 24; doi: 10.1111/ilr.12226. Epub 2021 Jul 24. PMID: 34548683; PMCID: PMC8444832.
Copy Download .nbib Format: NLM
Compliance with Prescription Guidelines for Glucose-Lowering Therapies According to Renal Function: Real-Life Study in Inpatients of Internal Medicine, Endocrinology and Cardiology Units.

Medicina (Kaunas, Lithuania)

Lohan L, Galtier F, Manson T, Mura T, Castet-Nicolas A, Faure D, Chapet N, Leclercq F, Pasquié JL, Roubille F, Roubille C, Blain H, Guilpain P, Villiet M, Avignon A, Sultan A, Breuker C.
PMID: 34946320
Medicina (Kaunas). 2021 Dec 17;57(12). doi: 10.3390/medicina57121376.

No abstract available.

Cite
Lohan L, Galtier F, Manson T, et al. Compliance with Prescription Guidelines for Glucose-Lowering Therapies According to Renal Function: Real-Life Study in Inpatients of Internal Medicine, Endocrinology and Cardiology Units. Medicina (Kaunas). 2021;57(12)doi: 10.3390/medicina57121376.
Lohan, L., Galtier, F., Manson, T., Mura, T., Castet-Nicolas, A., Faure, D., Chapet, N., Leclercq, F., Pasquié, J. L., Roubille, F., Roubille, C., Blain, H., Guilpain, P., Villiet, M., Avignon, A., Sultan, A., & Breuker, C. (2021). Compliance with Prescription Guidelines for Glucose-Lowering Therapies According to Renal Function: Real-Life Study in Inpatients of Internal Medicine, Endocrinology and Cardiology Units. Medicina (Kaunas, Lithuania), 57(12), . https://doi.org/10.3390/medicina57121376
Lohan, Laura, et al. "Compliance with Prescription Guidelines for Glucose-Lowering Therapies According to Renal Function: Real-Life Study in Inpatients of Internal Medicine, Endocrinology and Cardiology Units." Medicina (Kaunas, Lithuania) vol. 57,12 (2021). doi: https://doi.org/10.3390/medicina57121376
Lohan L, Galtier F, Manson T, Mura T, Castet-Nicolas A, Faure D, Chapet N, Leclercq F, Pasquié JL, Roubille F, Roubille C, Blain H, Guilpain P, Villiet M, Avignon A, Sultan A, Breuker C. Compliance with Prescription Guidelines for Glucose-Lowering Therapies According to Renal Function: Real-Life Study in Inpatients of Internal Medicine, Endocrinology and Cardiology Units. Medicina (Kaunas). 2021 Dec 17;57(12). doi: 10.3390/medicina57121376. PMID: 34946320.
Copy Download .nbib Format: NLM
Soluble urokinase-type plasminogen activator receptor strongly predicts global mortality in acute heart failure patients: insight from the STADE-HF registry.

Future science OA

Huet F, Dupuy AM, Duflos C, Reis CA, Kuster N, Aguilhon S, Cristol JP, Roubille F.
PMID: 34046195
Future Sci OA. 2021 Mar 29;7(5):FSO697. doi: 10.2144/fsoa-2020-0197.

BACKGROUND: Whether soluble urokinase-type plasminogen activator receptor (suPAR) could be a valuable prognostic indicator remains uncertain.MATERIALS & METHODS: Patients from STADE-HF (Soluble Suppression of Tumorigenesis-2 as a Help for Management of Diagnosis, Evaluation and Management of Heart Failure) were...

Cite
Huet F, Dupuy AM, Duflos C, et al. Soluble urokinase-type plasminogen activator receptor strongly predicts global mortality in acute heart failure patients: insight from the STADE-HF registry. Future Sci OA. 2021;7(5):FSO697doi: 10.2144/fsoa-2020-0197.
Huet, F., Dupuy, A. M., Duflos, C., Reis, C. A., Kuster, N., Aguilhon, S., Cristol, J. P., & Roubille, F. (2021). Soluble urokinase-type plasminogen activator receptor strongly predicts global mortality in acute heart failure patients: insight from the STADE-HF registry. Future science OA, 7(5), FSO697. https://doi.org/10.2144/fsoa-2020-0197
Huet, Fabien, et al. "Soluble urokinase-type plasminogen activator receptor strongly predicts global mortality in acute heart failure patients: insight from the STADE-HF registry." Future science OA vol. 7,5 (2021): FSO697. doi: https://doi.org/10.2144/fsoa-2020-0197
Huet F, Dupuy AM, Duflos C, Reis CA, Kuster N, Aguilhon S, Cristol JP, Roubille F. Soluble urokinase-type plasminogen activator receptor strongly predicts global mortality in acute heart failure patients: insight from the STADE-HF registry. Future Sci OA. 2021 Mar 29;7(5):FSO697. doi: 10.2144/fsoa-2020-0197. PMID: 34046195; PMCID: PMC8147742.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 79 entries